Marketed in 47 countries across Europe, the Americas, parts of Asia, and North Africa, Glucophage is a globally distributed brand of metformin hydrochloride, classified within the category of medications used in diabetes and acting as a hypoglycaemic agent. For travellers and expatriates managing long-term diabetes therapy, it is one of the most recognisable brand names attached to one of the most prescribed oral antidiabetic molecules in the world.
Glucophage is prescribed in the management of type 2 diabetes mellitus and, in some markets, is also used in the context of obesity and metabolic concerns associated with the change of life. The structured indication list further down this page reflects the registered uses recognised by national regulators across the markets where Glucophage is sold, and these can vary modestly from one country to another.
Because Glucophage is so widely registered, patients moving between countries frequently encounter it on local pharmacy shelves — sometimes still as Glucophage, sometimes as a metformin-containing generic produced by a regional manufacturer. Markets where the brand is registered include Canada, China, Argentina, Egypt, and France, but packaging, prescription requirements, and available strengths differ from one regulatory system to another. A local pharmacist is well placed to confirm whether a metformin product on the shelf corresponds to what was prescribed at home.
Other medications used in diabetes are sold in many of the same markets under different molecules and brand names, and metformin itself is frequently combined with other antidiabetic ingredients in fixed-dose products. Decisions about substituting one antidiabetic for another, or moving between branded and generic metformin, belong with a healthcare provider who knows the patient's full clinical picture.
Glucophage is prescribed in the management of type 2 diabetes mellitus and is also used in some markets in the context of obesity and metabolic concerns associated with the change of life. It belongs to the broader category of medications used in diabetes, acting as a hypoglycaemic agent. The structured indication block further down this page lists the registered uses recognised by national regulators across the markets where Glucophage is sold.
Glucophage contains metformin hydrochloride, classified within the hypoglycaemic category of medications used in diabetes. Metformin is one of the most widely prescribed oral antidiabetic molecules in the world, and the same active ingredient is sold internationally under a long list of brand names — particularly in markets where the original patent has expired and multiple manufacturers produce metformin products in parallel.
Glucophage is marketed in 47 countries spanning Europe, the Americas, North Africa, and parts of Asia. Representative markets include Canada, China, Argentina, Egypt, France, Germany, and Chile. If your country is not represented in the structured list on this page, a local pharmacist can usually confirm whether metformin is available in that market under another brand name or as a generic equivalent.
Metformin hydrochloride circulates worldwide under a wide range of brand names, both as a single-ingredient product and as a component of fixed-dose combinations with other antidiabetic molecules. Other medications used in diabetes within the broader hypoglycaemic category also exist, although they are not freely interchangeable. To identify a local metformin-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Yes. Glucophage is a prescription medication, and antidiabetic therapy is calibrated to a patient's individual metabolic profile, kidney function, concurrent medications, and overall clinical picture. This is particularly relevant for travellers and people relocating between countries, where prescription pathways, available formulations, and brand names differ. Any decision to start, stop, switch, or substitute metformin should sit with a healthcare provider familiar with the patient.
